{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:39:58Z","timestamp":1786653598846,"version":"build-2736575974"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>This review discusses the potential of major histocompatibility complex (MHC) Class II constructs as stroke therapeutics. We focus on the delivery of MHC Class II construct, DRmQ, as a safe and effective treatment for ischemic stroke. DRmQ was observed to attenuate behavioral deficits and decrease microglia activation and proinflammatory cytokines, illustrating its ability to mitigate the secondary cell death following stroke. Similar anti-neuroinflammation treatments, such as transplantation of mesenchymal stem cells and mitochondrial transfers, are briefly discussed to provide further support that sequestration of inflammation stands as a robust therapeutic target for stroke.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/bc.bc_16_21","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T08:21:48Z","timestamp":1617092508000},"page":"37-40","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Major histocompatibility complex Class II-based therapy for stroke"],"prefix":"10.4103","volume":"7","author":[{"given":"Bella M.","family":"Gonzales-Portillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jea-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur A.","family":"Vandenbark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halina","family":"Offner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesario V.","family":"Borlongan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20240830","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0079-6123(00)27022-2","article-title":"Restoration of function by neural transplantation in the ischemic brain","volume":"127","author":"Nishino","year":"2000","journal-title":"Prog Brain Res"},{"key":"R2-9-20240830","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.pneurobio.2008.04.005","article-title":"Neural progenitor NT2N cell lines from teratocarcinoma for transplantation therapy in stroke","volume":"85","author":"Hara","year":"2008","journal-title":"Prog Neurobiol"},{"key":"R3-9-20240830","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1161\/STROKEAHA.108.533091","article-title":"Cell therapy for stroke: Remaining issues to address before embarking on clinical trials","volume":"40","author":"Borlongan","year":"2009","journal-title":"Stroke"},{"key":"R4-9-20240830","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s12975-018-0614-2","article-title":"Interleukin 6-mediated endothelial barrier disturbances can be attenuated by Blockade of the IL6 receptor expressed in brain microvascular endothelial cells","volume":"9","author":"Blecharz-Lang","year":"2018","journal-title":"Transl Stroke Res"},{"key":"R5-9-20240830","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12975-018-0680-5","article-title":"Enhancing base excision repair of mitochondrial DNA to reduce ischemic injury following reperfusion","volume":"10","author":"Simon","year":"2019","journal-title":"Transl Stroke Res"},{"key":"R6-9-20240830","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s12975-018-0652-9","article-title":"MMP10 promotes efficient thrombolysis after is-chemic stroke in mice with induced diabetes","volume":"10","author":"Navarro-Oviedo","year":"2018","journal-title":"Transl Stroke Res"},{"key":"R7-9-20240830","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s12975-018-0644-9","article-title":"PAI-1 but not PAI-2 gene deficiency attenuates ischemic brain injury after experimental stroke","volume":"10","author":"Griemert","year":"2018","journal-title":"Transl Stroke Res"},{"key":"R8-9-20240830","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neuint.2016.10.007","article-title":"Partial MHC Class II constructs as novel immunomodulatory therapy for stroke","volume":"107","author":"Benedek","year":"2017","journal-title":"Neurochem Int"},{"key":"R9-9-20240830","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.trsl.2019.04.009","article-title":"Targeting neutrophil extracellular traps enhanced tPA fibrinolysis for experi-mental intracerebral hemorrhage","volume":"211","author":"Tan","year":"2019","journal-title":"Transl Res"},{"key":"R10-9-20240830","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s11011-017-9991-6","article-title":"DR\u03b11-MOG-35-55 treatment reduces lesion volumes and improves neurological deficits after traumatic brain injury","volume":"32","author":"Yang","year":"2017","journal-title":"Metab Brain Dis"},{"key":"R11-9-20240830","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s12975-015-0436-4","article-title":"Partial MHC constructs treat thromboembolic ischemic stroke characterized by early immune expansion","volume":"7","author":"Dotson","year":"2016","journal-title":"Transl Stroke Res"},{"key":"R12-9-20240830","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12974-018-1393-0","article-title":"A novel neurotherapeutic for multiple sclerosis, ischemic injury, methamphetamine addiction, and traumatic brain injury","volume":"16","author":"Vandenbark","year":"2019","journal-title":"J Neuroinflammation"},{"key":"R13-9-20240830","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s12975-016-0514-2","article-title":"DR\u03b11-MOG-35-55 reduces permanent ischemic brain injury","volume":"8","author":"Wang","year":"2017","journal-title":"Transl Stroke Res"},{"key":"R14-9-20240830","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11011-018-0331-2","article-title":"Increased CD74 binding and EAE treatment efficacy of a modified DR\u03b11 molecular construct","volume":"34","author":"Meza-Romero","year":"2019","journal-title":"Metab Brain Dis"},{"key":"R15-9-20240830","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s11011-013-9440-0","article-title":"A novel HLA-DR\u03b11-MOG-35-55 construct treats experimental stroke","volume":"29","author":"Benedek","year":"2014","journal-title":"Metab Brain Dis"},{"key":"R16-9-20240830","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1161\/STROKEAHA.109.552554","article-title":"Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials","volume":"40","author":"Saver","year":"2009","journal-title":"Stroke"},{"key":"R17-9-20240830","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s12975-019-00756-1","article-title":"A novel partial MHC Class II construct, DRmQ, inhibits central and peripheral inflammatory responses to promote neuroprotection in experimental stroke","volume":"11","author":"Lee","year":"2020","journal-title":"Transl Stroke Res"},{"key":"R18-9-20240830","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1007\/s12975-014-0348-8","article-title":"Recombinant T cell receptor ligand treatment improves neurological outcome in the presence of tissue plasminogen activator in experimental ischemic stroke","volume":"5","author":"Zhu","year":"2014","journal-title":"Transl Stroke Res"},{"key":"R19-9-20240830","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3324\/haematol.2018.206581","article-title":"Human stem cells transplanted into the rat stroke brain migrate to the spleen via lymphatic and inflammation pathways","volume":"104","author":"Xu","year":"2019","journal-title":"Haematologica"},{"key":"R20-9-20240830","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s12975-014-0345-y","article-title":"Novel humanized recombinant T cell receptor ligands protect the female brain after experimental stroke","volume":"5","author":"Pan","year":"2014","journal-title":"Transl Stroke Res"},{"key":"R21-9-20240830","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12974-018-1239-9","article-title":"The splenic response to stroke: From rodents to stroke subjects","volume":"15","author":"Seifert","year":"2018","journal-title":"J Neuroinflammation"},{"key":"R22-9-20240830","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1007\/s11011-018-0266-7","article-title":"Antibiotics protect against EAE by increasing regulatory and anti-inflammatory cells","volume":"33","author":"Seifert","year":"2018","journal-title":"Metab Brain Dis"},{"key":"R23-9-20240830","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s12975-014-0373-7","article-title":"Preclinical evaluation of recombinant T cell receptor ligand RTL1000 as a therapeutic agent in ischemic stroke","volume":"6","author":"Zhu","year":"2015","journal-title":"Transl Stroke Res"},{"key":"R24-9-20240830","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1161\/01.RES.0000135902.99383.6f","article-title":"Mesenchymal stem cells and their potential as cardiac therapeutics","volume":"95","author":"Pittenger","year":"2004","journal-title":"Circ Res"},{"key":"R25-9-20240830","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1161\/STROKEAHA.107.502047","article-title":"Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia","volume":"39","author":"Walczak","year":"2008","journal-title":"Stroke"},{"key":"R26-9-20240830","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1002\/eji.200636416","article-title":"Immunoregulatory function of mesenchymal stem cells","volume":"36","author":"Uccelli","year":"2006","journal-title":"Eur J Immunol"},{"key":"R27-9-20240830","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1161\/STROKEAHA.113.001943","article-title":"Vasculogenesis in experimental stroke after human cerebral endothelial cell transplantation","volume":"44","author":"Ishikawa","year":"2013","journal-title":"Stroke"},{"key":"R28-9-20240830","doi-asserted-by":"crossref","first-page":"3703","DOI":"10.1097\/00001756-199811160-00025","article-title":"Cerebral ischemia and CNS transplantation: Differential effects of grafted fetal rat striatal cells and human neurons derived from a clonal cell line","volume":"9","author":"Borlongan","year":"1998","journal-title":"Neuroreport"},{"key":"R29-9-20240830","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1527-5299.2005.03618.x","article-title":"Mesenchymal stem cells: Future source for reparative medicine","volume":"11","author":"Bhatia","year":"2005","journal-title":"Congest Heart Fail"},{"key":"R30-9-20240830","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4103\/2394-8108.192522","article-title":"Intra-arterial delivery of mesenchymal stem cells","volume":"2","author":"Watanabe","year":"2016","journal-title":"Brain Circ"},{"key":"R31-9-20240830","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.pneurobio.2013.11.007","article-title":"Cell based therapies for ischemic stroke: From basic science to bedside","volume":"115","author":"Liu","year":"2014","journal-title":"Prog Neurobiol"},{"key":"R32-9-20240830","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0022-510X(01)00557-3","article-title":"Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats","volume":"189","author":"Chen","year":"2001","journal-title":"J Neurol Sci"},{"key":"R33-9-20240830","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.atherosclerosis.2012.03.017","article-title":"Advances in cell-based therapy for peripheral vascular disease","volume":"223","author":"Blum","year":"2012","journal-title":"Atherosclerosis"},{"key":"R34-9-20240830","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4103\/bc.bc_14_18","article-title":"Mitochondrial targeting as a novel therapy for stroke","volume":"4","author":"Russo","year":"2018","journal-title":"Brain Circ"},{"key":"R35-9-20240830","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.nbd.2018.09.011","article-title":"Stem cell therapy for neurological disorders: A focus on aging","volume":"126","author":"Nguyen","year":"2019","journal-title":"Neurobiol Dis"},{"key":"R36-9-20240830","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pneurobio.2017.07.004","article-title":"Stem cell therapy for abrogating stroke-induced neuroinflammation and relevant secondary cell death mechanisms","volume":"158","author":"Stonesifer","year":"2017","journal-title":"Prog Neurobiol"}],"container-title":["Brain Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/bc.bc_16_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:39:50Z","timestamp":1786649990000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/bc.bc_16_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/bc.bc_16_21","relation":{},"ISSN":["2394-8108"],"issn-type":[{"value":"2394-8108","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}